# 💊 Pharma | GLP-1 Receptor Agonist Market Trends

This project explores the explosive growth of GLP-1 receptor agonist drugs such as Ozempic, Wegovy, and Mounjaro—analyzing manufacturer dominance, delivery innovation, and implications for public health. Using Tableau, I visualized year-over-year revenue trends and therapeutic market shifts driven by these drugs.


🔗 *[View Tableau Dashboard Here!!](https://public.tableau.com/views/GLP-1MarketTrendsTherapeuticExpansion20192023/Dashboard1?:language=en-US&publish=yes&:sid=&:redirect=auth&:display_count=n&:origin=viz_share_link)*

---

## 🎯 Project Objectives

- Visualize sales trends of GLP-1 drugs across regions and years
- Analyze manufacturer market share and drug-specific revenue
- Highlight innovation in delivery methods and therapeutic indications
- Provide data-driven insights on how GLP-1 drugs are reshaping pharma

---

## 🛠️ Tools Used

- **Google Sheets** – Manual curation of GLP-1 drug data  
- **Tableau** – Interactive dashboard creation  

---

## 📊 Dataset Features

| Column               | Description                                       |
|----------------------|---------------------------------------------------|
| `Drug Name`          | e.g., Ozempic, Wegovy, Mounjaro                   |
| `Company`            | Manufacturer name                                 |
| `Approval Year`      | FDA approval year                                 |
| `Year`               | Yearly revenue record                             |
| `Region`             | Region of sale (Global or U.S.)                   |
| `Revenue (USD)`      | Estimated revenue in USD                          |
| `Primary Indication` | Diabetes, Obesity, etc.                           |
| `Delivery Method`    | Oral or Injectable                                |
| `Dosage Frequency`   | Daily or Weekly                                   |

🔗 [Download Dataset](sandbox:/mnt/data/GLP1_Market_Trends_Cleaned.csv)

---

## 📈 Tableau Dashboard Highlights

▶ **Revenue by Drug Over Time**  
▶ **Top Manufacturers by Market Share**  
▶ **Approval Timeline by Indication**  
▶ **Indication × Delivery Method Matrix**  
▶ **Regional Revenue Comparison**

> 💡 Filters included: Year, Region, Company, Indication

---

## 🔍 Key Insights

- **Ozempic** leads in revenue, surpassing $11B in 2023 globally
- **Wegovy** shows rapid growth in obesity treatment since 2021
- **Mounjaro** gained major share quickly since its 2022 approval
- **Injectables dominate**, but oral options like Rybelsus are gaining traction
- Novo Nordisk and Eli Lilly are the top players, controlling >90% of the GLP-1 market

---
